RESUMO
Objective To study the clinical application value of plasma M2 pyruvate kinase (M2-PK),serum tumor marker carcinoembryonic antigen (CEA) and serum level of integrin-like protein-8 (ADAM8) in the diagnosis of Non-small cell lung cancer (NSCLC).Methods Seventy-five patients with NSCLC admitted to our hospital from April 2014 to August 2016 were randomly selected as study group.Seventy-five healthy subjects were randomly selected as control group.Serum ADAM8 and M2-PK levels were measured by enzyme-linked immunosorbent assay (ELISA) in all subjects,and serum CEA levels were determined by electrochemiluminescence (ECLIA).The clinical value of M2-PK,CEA and ADAM8 in diagnosis of NSCLC were analyzed by ROC curve.Results The levels of M2-PK,CEA and ADAM8 in the study group were significantly higher than those in the control group (P ＜ 0.05).The levels of M2-PK and CEA in patients with adenocarcinoma were significantly higher than those in squamous cell carcinoma patients (P ＜0.05),and the levels of M2-PK,CEA and ADAM8 in stage Ⅲ-Ⅳ patients were significantly higher than those in stage Ⅰ-Ⅱ patients (P ＜ 0.05).The AUC of M2-PK,CEA and ADAM8 combined detection (0.924) was significantly higher than that of M2-PK,CEA and ADAM8 separate detection (0.731,0.858 and 0.790),and the difference was statistically significant (P ＜ 0.05).The sensitivity and specificity of M2-PK,CEA and ADAM8 combined detection were significantly higher than those of M2-PK,CEA and ADAM8 separate detection (P ＜ 0.05).Conclusion The value of M2-PK,CEA and ADAM8 in diagnosing NSCLC has a certain clinical value,and the diagnostic value of M2-PK,CEA and ADAM8combined detection is superior to that of separate detection,and M2-PK,CEA and ADAM8 combined detection worthy of clinical application.
RESUMO
BACKGROUND/AIMS: Pyruvate kinase (PK) is a key enzyme of glycolysis. Different isoforms of this enzyme are tissue-specifically expressed (M2-PK, M1-PK, R-PK, L-PK). The concentration of the dimeric M2-PK is increased in a metabolic state of tumor cells. In this case, the dimeric M2-PK is termed Tumor M2-PK. We investigated EDTA-plasma of 73 patients with gastrointestinal (GI) cancer and 61 healthy controls to evaluate its significance in diagnosing GI cancer. METHODS: Plasma Tumor M2-PK was measured using an ELISA assay based on two monoclonal antibodies which specifically react with the dimeric Tumor M2-PK. RESULTS: The sensitivity of Tumor M2-PK was 67.1% for all GI cancers, that of CA 19-9 was 38.4% and that of CEA was 34.3%. The specificity of Tumor M2-PK was 91.8% (cutoff=20 U/mL). Tumor M2-PK showed a high sensitivity in gastric cancer (62.2%), colorectal cancer (66.7%) and bile duct cancer (75.0%). In colorectal cancer, the combination of Tumor M2-PK with CEA resulted in a remarkable increase in the sensitivity (86.2%). The average Tumor M2-PK levels were generally elevated in the metastatic GI cancer patients compared to nonmetastatic patients, especially in stomach cancer with statistical significance (p=0.005). CONCLUSIONS: Tumor M2-PK in EDTA-plasma seems to be a new valuable tumor marker in GI cancer.